Is there a role for chemotherapy in nonmetastatic prostate cancer?

Daniel Keizman, Mario Eisenberger

Research output: Contribution to journalArticle

Abstract

Purpose of review Prognostic clinical, pathological, and molecular parameters identify patients with nonmetastatic prostate cancer that are at risk for the development of future metastatic disease and shorter survival. In metastatic castration-resistant prostate cancer, docetaxel-based chemotherapy prolongs survival and improves quality of life, and is the standard of care. It may be rational to hypothesize that early utilization of chemotherapy may delay the onset of distant metastasis and prolong survival in the earlier nonmetastatic disease. A discussion on ongoing clinical trials and natural history aspects applicable to clinical trials design in this setting are presented herein. Recent findings Preliminary data suggest that chemotherapy is well tolerated, feasible, and potentially active in nonmetastatic prostate cancer. However, results from prospective randomized trials were not published yet. Summary In nonmetastatic prostate cancer, application of chemotherapy remains an open question awaiting prospective validation and should be routinely applied outside of clinical trials. In view of the long natural history, evaluation of conventional endpoints as time to distant metastasis and survival are challenging even in the high-risk patients. Appropriate patient selection based on predictive biomarkers and surrogate endpoints may provide critical information for patient selection and study design.

Original languageEnglish (US)
Pages (from-to)141-146
Number of pages6
JournalCurrent Opinion in Supportive and Palliative Care
Volume4
Issue number3
DOIs
StatePublished - Sep 2010
Externally publishedYes

Fingerprint

Prostatic Neoplasms
Drug Therapy
Survival
Clinical Trials
docetaxel
Natural History
Patient Selection
Biomarkers
Neoplasm Metastasis
Castration
Standard of Care
Quality of Life

Keywords

  • Chemotherapy
  • Docetaxel
  • Nonmetastatic prostate cancer

ASJC Scopus subject areas

  • Oncology
  • Medicine(all)
  • Critical Care and Intensive Care Medicine
  • Oncology(nursing)

Cite this

Is there a role for chemotherapy in nonmetastatic prostate cancer? / Keizman, Daniel; Eisenberger, Mario.

In: Current Opinion in Supportive and Palliative Care, Vol. 4, No. 3, 09.2010, p. 141-146.

Research output: Contribution to journalArticle

@article{a6c9bcae2d9a496781d6de43fdd523eb,
title = "Is there a role for chemotherapy in nonmetastatic prostate cancer?",
abstract = "Purpose of review Prognostic clinical, pathological, and molecular parameters identify patients with nonmetastatic prostate cancer that are at risk for the development of future metastatic disease and shorter survival. In metastatic castration-resistant prostate cancer, docetaxel-based chemotherapy prolongs survival and improves quality of life, and is the standard of care. It may be rational to hypothesize that early utilization of chemotherapy may delay the onset of distant metastasis and prolong survival in the earlier nonmetastatic disease. A discussion on ongoing clinical trials and natural history aspects applicable to clinical trials design in this setting are presented herein. Recent findings Preliminary data suggest that chemotherapy is well tolerated, feasible, and potentially active in nonmetastatic prostate cancer. However, results from prospective randomized trials were not published yet. Summary In nonmetastatic prostate cancer, application of chemotherapy remains an open question awaiting prospective validation and should be routinely applied outside of clinical trials. In view of the long natural history, evaluation of conventional endpoints as time to distant metastasis and survival are challenging even in the high-risk patients. Appropriate patient selection based on predictive biomarkers and surrogate endpoints may provide critical information for patient selection and study design.",
keywords = "Chemotherapy, Docetaxel, Nonmetastatic prostate cancer",
author = "Daniel Keizman and Mario Eisenberger",
year = "2010",
month = "9",
doi = "10.1097/SPC.0b013e32833c6cfe",
language = "English (US)",
volume = "4",
pages = "141--146",
journal = "Current Opinion in Supportive and Palliative Care",
issn = "1751-4258",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Is there a role for chemotherapy in nonmetastatic prostate cancer?

AU - Keizman, Daniel

AU - Eisenberger, Mario

PY - 2010/9

Y1 - 2010/9

N2 - Purpose of review Prognostic clinical, pathological, and molecular parameters identify patients with nonmetastatic prostate cancer that are at risk for the development of future metastatic disease and shorter survival. In metastatic castration-resistant prostate cancer, docetaxel-based chemotherapy prolongs survival and improves quality of life, and is the standard of care. It may be rational to hypothesize that early utilization of chemotherapy may delay the onset of distant metastasis and prolong survival in the earlier nonmetastatic disease. A discussion on ongoing clinical trials and natural history aspects applicable to clinical trials design in this setting are presented herein. Recent findings Preliminary data suggest that chemotherapy is well tolerated, feasible, and potentially active in nonmetastatic prostate cancer. However, results from prospective randomized trials were not published yet. Summary In nonmetastatic prostate cancer, application of chemotherapy remains an open question awaiting prospective validation and should be routinely applied outside of clinical trials. In view of the long natural history, evaluation of conventional endpoints as time to distant metastasis and survival are challenging even in the high-risk patients. Appropriate patient selection based on predictive biomarkers and surrogate endpoints may provide critical information for patient selection and study design.

AB - Purpose of review Prognostic clinical, pathological, and molecular parameters identify patients with nonmetastatic prostate cancer that are at risk for the development of future metastatic disease and shorter survival. In metastatic castration-resistant prostate cancer, docetaxel-based chemotherapy prolongs survival and improves quality of life, and is the standard of care. It may be rational to hypothesize that early utilization of chemotherapy may delay the onset of distant metastasis and prolong survival in the earlier nonmetastatic disease. A discussion on ongoing clinical trials and natural history aspects applicable to clinical trials design in this setting are presented herein. Recent findings Preliminary data suggest that chemotherapy is well tolerated, feasible, and potentially active in nonmetastatic prostate cancer. However, results from prospective randomized trials were not published yet. Summary In nonmetastatic prostate cancer, application of chemotherapy remains an open question awaiting prospective validation and should be routinely applied outside of clinical trials. In view of the long natural history, evaluation of conventional endpoints as time to distant metastasis and survival are challenging even in the high-risk patients. Appropriate patient selection based on predictive biomarkers and surrogate endpoints may provide critical information for patient selection and study design.

KW - Chemotherapy

KW - Docetaxel

KW - Nonmetastatic prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=78449285250&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78449285250&partnerID=8YFLogxK

U2 - 10.1097/SPC.0b013e32833c6cfe

DO - 10.1097/SPC.0b013e32833c6cfe

M3 - Article

C2 - 20613534

AN - SCOPUS:78449285250

VL - 4

SP - 141

EP - 146

JO - Current Opinion in Supportive and Palliative Care

JF - Current Opinion in Supportive and Palliative Care

SN - 1751-4258

IS - 3

ER -